MegaPro Biomedical Co., Ltd. (6827) Stock Statistics & Valuation Metrics
Total Valuation
MegaPro Biomedical Co., Ltd. has a market cap or net worth of TWD 1.06B. The enterprise value is ―.
- Market Cap
- TWD 1.06B
- Enterprise Value
- ―
Share Statistics
MegaPro Biomedical Co., Ltd. has 79,293,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 79,293,500
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
MegaPro Biomedical Co., Ltd.’s return on equity (ROE) is -0.45 and return on invested capital (ROIC) is -44.98%.
- Return on Equity (ROE)
- -0.45
- Return on Assets (ROA)
- -0.43
- Return on Invested Capital (ROIC)
- -44.98%
- Return on Capital Employed (ROCE)
- -0.45
- Revenue Per Employee
- 0
- Profits Per Employee
- -4.41M
- Employee Count
- 27
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of MegaPro Biomedical Co., Ltd. is -11.62. MegaPro Biomedical Co., Ltd.’s PEG ratio is -0.12.
- PE Ratio
- -11.62
- PS Ratio
- 0.00
- PB Ratio
- 5.42
- Price to FCF
- -11.74
- Price to Operating Cash Flow
- -11.68
- PEG Ratio
- -0.12
Income Statement
In the last 12 months, MegaPro Biomedical Co., Ltd. had revenue of 0 and earned -119.10M in profits. Earnings per share was -1.77.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -119.59M
- Pretax Income
- -119.10M
- Net Income
- -119.10M
- EBITDA
- -103.91M
- Earnings Per Share (EPS)
- -1.77
Cash Flow
In the last 12 months, operating cash flow was -101.10M and capital expenditures -752,999, giving a free cash flow of -101.85M billion.
- Operating Cash Flow
- -101.10M
- Free Cash Flow
- -101.85M
- Free Cash Flow per Share
- -1.30
Dividends & Yields
MegaPro Biomedical Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -8.43%
- Earnings Yield
- -8.54%
Stock Price Statistics
- Beta
- 0.60
- 52-Week Price Change
- -16.25%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 48.52
- Average Volume (3m)
- 529.14K
Financial Position
MegaPro Biomedical Co., Ltd. as a current ratio of 16.17, with Debt / Equity ratio of 1.10%
- Current Ratio
- 16.17
- Quick Ratio
- 16.17
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.05
- Interest Coverage Ratio
- -866.57
Taxes
In the past 12 months, MegaPro Biomedical Co., Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
MegaPro Biomedical Co., Ltd. EV to EBITDA ratio is -12.21, with an EV/FCF ratio of -11.01.
- EV to Sales
- 0.00
- EV to EBITDA
- -12.21
- EV to Free Cash Flow
- -11.01
- EV to Operating Cash Flow
- -11.09
Balance Sheet
MegaPro Biomedical Co., Ltd. has TWD 190.08M in cash and marketable securities with TWD 1.46M in debt, giving a net cash position of TWD 188.62M billion.
- Cash & Marketable Securities
- TWD 190.08M
- Total Debt
- TWD 1.46M
- Net Cash
- TWD 188.62M
- Net Cash Per Share
- TWD 2.38
- Tangible Book Value Per Share
- TWD 2.72
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for MegaPro Biomedical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 42.52%
